{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:53:36Z","timestamp":1761155616196},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.thromres.2012.08.277","type":"journal-article","created":{"date-parts":[[2012,9,29]],"date-time":"2012-09-29T00:07:05Z","timestamp":1348877225000},"page":"S59-S60","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S1","title":["Antithrombotic treatment of atrial fibrillation: New insights"],"prefix":"10.1016","volume":"130","author":[{"given":"J.Y.","family":"Le Heuzey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2012.08.277_bb0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.acvd.2010.11.012","article-title":"Epidemiology of atrial fibrillation in France : extrapolation of international epidemiological data to France and analysis of french hospitalisation data","volume":"104","author":"Charlemagne","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.thromres.2012.08.277_bb0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0002-8703(03)00524-6","article-title":"Cost Of Care distribution in Atrial Fibrillation patients : the COCAF study","volume":"147","author":"Le Heuzey","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2012.08.277_bb0025","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2012.08.277_bb0035","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2012.08.277_bb0045","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1093\/eurheartj\/ehm308","article-title":"Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF)","volume":"28","author":"Friberg","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2012.08.277_bb0055","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2012.08.277_bb0065","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in patients with atrial fibrillation","volume":"17","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2012.08.277_bb0075","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2012.08.277_bb0085","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"AVERROES committees and investigators. Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2012.08.277_bb0090","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"ARISTOTLE committees and investigators Apixaban versus Warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384812006494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384812006494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T12:27:42Z","timestamp":1542716862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384812006494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":10,"alternative-id":["S0049384812006494"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2012.08.277","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}